(Q28086973)

28 October 2020

anti-inflammatory agent

1 reference

19 July 2021

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Philippe Eigenmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Amy S. Paller

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Carle Paul

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Jonathan M. Spergel

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

21

Georg Stingl

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

25

Ulrich Wahn

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

2

Mark Boguniewicz

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

11

Eckard Hamelmann

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

13

Antonella Muraro

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Thomas Luger

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Warner Carr

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Mette Deleuran

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Lawrence Eichenfield

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Regina Fölster-Holst

8

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Carlo Gelmetti

9

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Harald Gollnick

10

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Luis Puig

17

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Johannes Ring

18

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Elaine Siegfried

19

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Alain Taieb

22

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Antonio Torrelo

23

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Thomas Werfel

24

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Adelaide A Hebert

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Arnold P Oranje

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

1 reference

June 2015

1 reference

Pediatric Allergy & Immunology

1 June 2015

8 references

12 March 2019

13 March 2019

22 April 2019

17 June 2019

11 November 2019

24 July 2020

28 October 2020

19 July 2021

10 references

12 March 2019

13 March 2019

22 April 2019

17 June 2019

11 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

24 July 2020

28 October 2020

19 July 2021

26

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

306-315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

13 June 2020

copyright license

8 references

12 March 2019

13 March 2019

22 April 2019

17 June 2019

11 November 2019

24 July 2020

28 October 2020

on focus list of Wikimedia project

19 July 2021

ScienceSource

0 references

cites work

Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Complementary and alternative medicines and childhood eczema: a US population-based study

20 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

20 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Atopic dermatitis: a practice parameter update 2012.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

The Safety and Efficacy of Tacrolimus Ointment in Pediatric Patients with Atopic Dermatitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Quality-of-life Outcomes and Measurement in Childhood Atopic Dermatitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Association between exposure to topical tacrolimus or pimecrolimus and cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

The socioeconomic impact of atopic dermatitis in the United States: a systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Adverse effects of topical glucocorticosteroids

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Pimecrolimus -- an anti-inflammatory drug targeting the skin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Atopic dermatitis and the atopic march

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Secondary infections in patients with atopic dermatitis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic DermatitisStudy Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

Microbial contamination and preservative efficacy of topical creams.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

2 June 2018

1 reference

The natural course of atopic dermatitis from birth to age 7 years and the association with asthma

21 January 2018

1 reference

The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma.

21 January 2018

1 reference

The prevalence of atopic triad in children with physician-confirmed atopic dermatitis.

21 January 2018

1 reference

Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients

21 January 2018

1 reference

Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study

21 January 2018

1 reference

Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls?

21 January 2018

1 reference

Guidelines for treatment of atopic eczema (atopic dermatitis) part I.

21 January 2018

1 reference

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

21 January 2018

1 reference

Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis

21 January 2018

1 reference

Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency.

21 January 2018

1 reference

Topical corticosteroid phobia in patients with atopic eczema

21 January 2018

1 reference

The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis

21 January 2018

1 reference

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

21 January 2018

1 reference

Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.

21 January 2018

1 reference

Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study

21 January 2018

1 reference

Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.

21 January 2018

1 reference

Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study

21 January 2018

1 reference

Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.

21 January 2018

1 reference

First experience of topical SDZ ASM 981 in children with atopic dermatitis

21 January 2018

1 reference

Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study

21 January 2018

1 reference

Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination

21 January 2018

1 reference

Consensus statement on the safety profile of topical calcineurin inhibitors

21 January 2018

1 reference

Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?

21 January 2018

1 reference

Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients

21 January 2018

1 reference

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

21 January 2018

1 reference

Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4657476

27 November 2018

1 reference

Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids

21 January 2018

1 reference

12 December 2020

Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography

1 reference

12 December 2020

Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice

1 reference

12 December 2020

Regional variation in percutaneous penetration of 14C cortisol in man

1 reference

12 December 2020

Lymphomas after solid organ transplantation: a collaborative transplant study report

1 reference

12 December 2020

Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study

1 reference

12 December 2020

Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis

1 reference

12 December 2020

Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis

1 reference

12 December 2020

Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults

1 reference

12 December 2020

Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis

1 reference

12 December 2020

Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis

1 reference

12 December 2020

Effect of hydrocortisone, methylprednisolone aceponate and momethasone furoate on collagen synthesis in human skin in vivo

1 reference

12 December 2020

The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo

1 reference

12 December 2020

Infant skin microstructure assessed in vivo differs from adult skin in organization and at the cellular level

1 reference

12 December 2020

Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease

1 reference

12 December 2020

Identifiers

DOI

10.1111/PAI.12331

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557211%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

PubMed publication ID

2 references